Emergex Vaccines is a pioneering biotechnology company focused on improving global human health by providing long-term immunity against urgent infectious diseases. Headquartered in Oxfordshire, Abingdon, UK, with R&D facilities in Milton Park, UK, and an operating subsidiary in Doylestown, Pennsylvania, Emergex is at the forefront of developing 100% synthetic CD8+ T cell-priming immune set-point candidates. These candidates combine two proprietary technologies to offer broad and robust protection against viruses within the same family, as well as existing and potential variants.

They also provide long-lasting immune protection for decades and can be stored at room temperature, eliminating the need for cold chain requirements. Emergex's vaccines are administered via intradermal micro-needles, offering a needle-free alternative to traditional injection methods. Moreover, their rapid development and scale-up are facilitated by an ultrasmall passivated nanocluster delivery platform.

With its innovative approach, Emergex Vaccines is revolutionizing the field of immunization and working towards a world free from the threat of infectious diseases